Annual FCF
-$197.90 M
-$81.92 M-70.62%
December 31, 2023
Summary
- As of February 8, 2025, INBX annual free cash flow is -$197.90 million, with the most recent change of -$81.92 million (-70.62%) on December 31, 2023.
- During the last 3 years, INBX annual FCF has fallen by -$148.57 million (-301.16%).
- INBX annual FCF is now -884.98% below its all-time high of -$20.09 million, reached on December 31, 2017.
Performance
INBX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$30.53 M
+$50.78 M+62.45%
September 30, 2024
Summary
- As of February 8, 2025, INBX quarterly free cash flow is -$30.53 million, with the most recent change of +$50.78 million (+62.45%) on September 30, 2024.
- Over the past year, INBX quarterly FCF has increased by +$50.78 million (+62.45%).
- INBX quarterly FCF is now -855.83% below its all-time high of $4.04 million, reached on December 31, 2023.
Performance
INBX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$149.23 M
+$24.53 M+14.12%
September 30, 2024
Summary
- As of February 8, 2025, INBX TTM free cash flow is -$149.23 million, with the most recent change of +$24.53 million (+14.12%) on September 30, 2024.
- Over the past year, INBX TTM FCF has increased by +$24.53 million (+14.12%).
- INBX TTM FCF is now -6717.31% below its all-time high of -$2.19 million, reached on March 31, 2018.
Performance
INBX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
INBX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -70.6% | +62.5% | +14.1% |
| 3 y3 years | -301.2% | -13.2% | -28.8% |
| 5 y5 years | -707.1% | -13.2% | -28.8% |
INBX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -143.8% | at low | -855.8% | +62.5% | -83.8% | +14.1% |
| 5 y | 5-year | -484.0% | at low | -855.8% | +62.5% | -353.4% | +14.1% |
| alltime | all time | -885.0% | at low | -855.8% | +62.5% | -6717.3% | +14.1% |
Inhibrx Biosciences Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$30.53 M(-62.5%) | -$149.23 M(-14.1%) |
| Jun 2024 | - | -$81.31 M(+96.2%) | -$173.76 M(+17.3%) |
| Mar 2024 | - | -$41.43 M(-1125.8%) | -$148.07 M(+10.8%) |
| Dec 2023 | -$197.90 M(+70.6%) | $4.04 M(-107.3%) | -$133.60 M(-20.7%) |
| Sep 2023 | - | -$55.06 M(-1.0%) | -$168.51 M(+16.8%) |
| Jun 2023 | - | -$55.62 M(+106.3%) | -$144.27 M(+24.5%) |
| Mar 2023 | - | -$26.96 M(-12.7%) | -$115.89 M(-0.1%) |
| Dec 2022 | -$115.99 M(+42.9%) | -$30.87 M(+0.2%) | -$115.99 M(+7.4%) |
| Sep 2022 | - | -$30.82 M(+13.1%) | -$108.01 M(+18.6%) |
| Jun 2022 | - | -$27.24 M(+0.7%) | -$91.03 M(+5.1%) |
| Mar 2022 | - | -$27.06 M(+18.2%) | -$86.58 M(+6.6%) |
| Dec 2021 | -$81.19 M | -$22.89 M(+65.3%) | -$81.19 M(+9.3%) |
| Sep 2021 | - | -$13.84 M(-39.3%) | -$74.30 M(-0.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$22.79 M(+5.2%) | -$74.64 M(+17.5%) |
| Mar 2021 | - | -$21.66 M(+35.4%) | -$63.52 M(+28.8%) |
| Dec 2020 | -$49.33 M(+45.6%) | -$16.00 M(+12.8%) | -$49.33 M(+8.2%) |
| Sep 2020 | - | -$14.18 M(+21.5%) | -$45.61 M(+38.6%) |
| Jun 2020 | - | -$11.67 M(+56.1%) | -$32.91 M(-7.8%) |
| Mar 2020 | - | -$7.48 M(-39.1%) | -$35.71 M(+5.4%) |
| Dec 2019 | -$33.89 M(+38.2%) | -$12.28 M(+727.3%) | -$33.89 M(+56.8%) |
| Sep 2019 | - | -$1.48 M(-89.7%) | -$21.61 M(+7.4%) |
| Jun 2019 | - | -$14.47 M(+156.0%) | -$20.13 M(+5.0%) |
| Mar 2019 | - | -$5.65 M(-58.2%) | -$19.17 M(+22.1%) |
| Dec 2018 | -$24.52 M(+22.0%) | - | - |
| Jun 2018 | - | -$13.52 M(+517.5%) | -$15.71 M(+617.5%) |
| Mar 2018 | - | -$2.19 M | -$2.19 M |
| Dec 2017 | -$20.09 M | - | - |
FAQ
- What is Inhibrx Biosciences annual free cash flow?
- What is the all time high annual FCF for Inhibrx Biosciences?
- What is Inhibrx Biosciences annual FCF year-on-year change?
- What is Inhibrx Biosciences quarterly free cash flow?
- What is the all time high quarterly FCF for Inhibrx Biosciences?
- What is Inhibrx Biosciences quarterly FCF year-on-year change?
- What is Inhibrx Biosciences TTM free cash flow?
- What is the all time high TTM FCF for Inhibrx Biosciences?
- What is Inhibrx Biosciences TTM FCF year-on-year change?
What is Inhibrx Biosciences annual free cash flow?
The current annual FCF of INBX is -$197.90 M
What is the all time high annual FCF for Inhibrx Biosciences?
Inhibrx Biosciences all-time high annual free cash flow is -$20.09 M
What is Inhibrx Biosciences annual FCF year-on-year change?
Over the past year, INBX annual free cash flow has changed by -$81.92 M (-70.62%)
What is Inhibrx Biosciences quarterly free cash flow?
The current quarterly FCF of INBX is -$30.53 M
What is the all time high quarterly FCF for Inhibrx Biosciences?
Inhibrx Biosciences all-time high quarterly free cash flow is $4.04 M
What is Inhibrx Biosciences quarterly FCF year-on-year change?
Over the past year, INBX quarterly free cash flow has changed by +$50.78 M (+62.45%)
What is Inhibrx Biosciences TTM free cash flow?
The current TTM FCF of INBX is -$149.23 M
What is the all time high TTM FCF for Inhibrx Biosciences?
Inhibrx Biosciences all-time high TTM free cash flow is -$2.19 M
What is Inhibrx Biosciences TTM FCF year-on-year change?
Over the past year, INBX TTM free cash flow has changed by +$24.53 M (+14.12%)